SG10201510041QA - Humanized antibodies to liv-1 and use of same to treat cancer - Google Patents
Humanized antibodies to liv-1 and use of same to treat cancerInfo
- Publication number
- SG10201510041QA SG10201510041QA SG10201510041QA SG10201510041QA SG10201510041QA SG 10201510041Q A SG10201510041Q A SG 10201510041QA SG 10201510041Q A SG10201510041Q A SG 10201510041QA SG 10201510041Q A SG10201510041Q A SG 10201510041QA SG 10201510041Q A SG10201510041Q A SG 10201510041QA
- Authority
- SG
- Singapore
- Prior art keywords
- liv
- same
- humanized antibodies
- treat cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42029110P | 2010-12-06 | 2010-12-06 | |
| US201161446990P | 2011-02-25 | 2011-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201510041QA true SG10201510041QA (en) | 2016-01-28 |
Family
ID=46207694
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201510041QA SG10201510041QA (en) | 2010-12-06 | 2011-12-06 | Humanized antibodies to liv-1 and use of same to treat cancer |
| SG2013041926A SG190938A1 (en) | 2010-12-06 | 2011-12-06 | Humanized antibodies to liv-1 and use of same to treat cancer |
| SG10201912646UA SG10201912646UA (en) | 2010-12-06 | 2011-12-06 | Humanized antibodies to liv-1 and use of same to treat cancer |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013041926A SG190938A1 (en) | 2010-12-06 | 2011-12-06 | Humanized antibodies to liv-1 and use of same to treat cancer |
| SG10201912646UA SG10201912646UA (en) | 2010-12-06 | 2011-12-06 | Humanized antibodies to liv-1 and use of same to treat cancer |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9228026B2 (en) |
| EP (4) | EP3156420B1 (en) |
| JP (5) | JP6105481B2 (en) |
| KR (5) | KR20220011811A (en) |
| CN (1) | CN103533957B (en) |
| AU (4) | AU2011338480B8 (en) |
| BR (2) | BR122021020513B1 (en) |
| CA (2) | CA2819038C (en) |
| CY (3) | CY1118874T1 (en) |
| DK (3) | DK3156420T3 (en) |
| ES (3) | ES2719548T3 (en) |
| HR (1) | HRP20170567T1 (en) |
| HU (3) | HUE043355T2 (en) |
| IL (4) | IL299837A (en) |
| LT (1) | LT2648752T (en) |
| MX (2) | MX351027B (en) |
| NZ (1) | NZ611468A (en) |
| PL (3) | PL3156420T3 (en) |
| PT (3) | PT3156420T (en) |
| RS (1) | RS55843B1 (en) |
| RU (1) | RU2608646C2 (en) |
| SG (3) | SG10201510041QA (en) |
| SI (3) | SI3156420T1 (en) |
| WO (1) | WO2012078688A2 (en) |
| ZA (1) | ZA201303803B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3156420T3 (en) | 2010-12-06 | 2019-08-30 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| CA3124553A1 (en) | 2012-10-25 | 2014-05-01 | Bioverativ Usa Inc. | Anti-complement c1s antibodies and uses thereof |
| CN104884088B (en) | 2012-11-02 | 2018-06-15 | 美国比奥维拉迪维股份有限公司 | Anticomplement C1s antibody and its purposes |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| CN105007941B (en) | 2012-12-27 | 2019-01-25 | 赛诺菲 | Anti- LAMP1 antibody and antibody drug conjugates and application thereof |
| KR20230141929A (en) * | 2013-07-31 | 2023-10-10 | 암젠 인크 | Stabilization of fc-containing polypeptides |
| AU2014337555C1 (en) | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
| CA2937753A1 (en) | 2014-02-17 | 2015-08-20 | Seattle Genetics, Inc. | Hydrophilic antibody-drug conjugates |
| SI3280440T1 (en) | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| TWI814699B (en) | 2015-12-04 | 2023-09-11 | 美商思進公司 | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| CA3011900A1 (en) | 2016-02-17 | 2017-08-24 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| MA45324A (en) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
| JP7073266B2 (en) | 2016-03-25 | 2022-05-23 | シージェン インコーポレイテッド | Process for preparing PEGylated drug linkers and their intermediates |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| KR20190038579A (en) | 2016-08-09 | 2019-04-08 | 시애틀 지네틱스, 인크. | A drug conjugate with a self-stabilizing linker having improved physicochemical properties |
| EA201891851A1 (en) * | 2016-09-16 | 2019-04-30 | Сиэтл Дженетикс, Инк. | ANTIBODIES AGAINST BCMA AND THEIR APPLICATION FOR THE TREATMENT OF malignant neoplasms and immunological disorders |
| SG11201903013SA (en) | 2016-10-18 | 2019-05-30 | Seattle Genetics Inc | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| SG10202110183VA (en) | 2017-03-15 | 2021-10-28 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
| IL269398B2 (en) | 2017-03-24 | 2024-05-01 | Seagen Inc | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| US11305224B2 (en) | 2017-04-18 | 2022-04-19 | 3M Innovative Properties Company | Air filter media with post-pleat-deposited sorbent particles |
| KR20190141181A (en) | 2017-04-27 | 2019-12-23 | 시애틀 지네틱스, 인크. | Quaternized nicotinamide adenine dinucleotide rescue pathway inhibitors conjugates |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| CR20200145A (en) * | 2017-09-02 | 2020-08-03 | Abbvie Inc | Nti-egfr antibody drug conjugates (adc) and uses thereof |
| CA3073331A1 (en) * | 2017-09-02 | 2019-03-07 | Abbvie Inc. | Anti-egfr antibody drug conjugates (adc) and uses thereof |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| MA50943A (en) * | 2017-12-01 | 2020-10-07 | Seattle Genetics Inc | HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF BREAST CANCER |
| JP2021513990A (en) | 2018-02-20 | 2021-06-03 | シージェン インコーポレイテッド | Hydrophobic auristatin F compound and its conjugate |
| WO2020056192A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Antibody conjugates of toll-like receptor agonists |
| CA3112545A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| WO2020056194A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| CN113164618A (en) | 2018-09-12 | 2021-07-23 | 希沃尔拜克治疗公司 | Methods and compositions for treating diseases with immunostimulatory conjugates |
| KR20210089707A (en) * | 2018-11-07 | 2021-07-16 | 크리스퍼 테라퓨틱스 아게 | Anti-LIV1 Immune Cell Cancer Therapy |
| WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
| WO2020247572A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Masked antibody formulations |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US20210030885A1 (en) * | 2019-07-22 | 2021-02-04 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
| KR20220058555A (en) | 2019-08-15 | 2022-05-09 | 실버백 테라퓨틱스, 인크. | Formulations of benzazepine conjugates and uses thereof |
| AU2020358726A1 (en) | 2019-10-01 | 2022-04-07 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| US20210228676A1 (en) | 2019-12-09 | 2021-07-29 | Seagen Inc. | Combination Therapy With LIV1-ADC and PD-1 Antagonist |
| TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| EP4175673A1 (en) | 2020-07-01 | 2023-05-10 | ARS Pharmaceuticals Inc. | Anti-asgr1 antibody conjugates and uses thereof |
| CA3197158A1 (en) * | 2020-09-28 | 2022-03-31 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
| AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
| EP4370211A1 (en) | 2021-07-14 | 2024-05-22 | Seagen Inc. | Antibody masking domains |
| WO2023049825A1 (en) | 2021-09-24 | 2023-03-30 | Seagen Inc. | Improved antibody masking domains |
| WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
| WO2024109944A1 (en) * | 2022-11-25 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | Anti-liv-1 antibody, drug conjugate thereof, and medical use thereof |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (en) | 1982-01-22 | 1985-10-31 | Sandoz Ag | METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| DE68921982D1 (en) | 1988-06-14 | 1995-05-04 | Cetus Oncology Corp | COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (en) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgenic mice capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
| US5514554A (en) | 1991-08-22 | 1996-05-07 | Becton Dickinson And Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2156149T3 (en) | 1992-12-04 | 2001-06-16 | Medical Res Council | MULTIVALENT AND MULTI-SPECIFIC UNION PROTEINS, ITS MANUFACTURE AND USE. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| CA2132500A1 (en) | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
| ES2195036T3 (en) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | RAMIFIED HYDRAZONE CONNECTORS. |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| WO1998018945A1 (en) | 1996-10-31 | 1998-05-07 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| WO1998034118A1 (en) | 1997-01-30 | 1998-08-06 | Yale University | Diagnostic methods and compositions based on the distribution of rad51 |
| WO1999023230A1 (en) | 1997-10-31 | 1999-05-14 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| CA2309758A1 (en) | 1997-11-18 | 1999-05-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| CA2316397A1 (en) | 1997-12-24 | 1999-07-08 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| JP3422776B2 (en) | 1998-08-04 | 2003-06-30 | ダイアデクスアス・インコーポレーテッド | Novel method for diagnosing, monitoring, staging, imaging and treating breast cancer |
| EP1121437B1 (en) | 1998-10-15 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
| CA2625839A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US7285382B2 (en) | 2000-01-25 | 2007-10-23 | Genentech, Inc. | Compositions and methods for treatment of cancer |
| WO2001096372A2 (en) | 2000-06-13 | 2001-12-20 | University College Cardiff Consultants Ltd | Zinc transporters proteins and their use in medicinal preparations |
| US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003004989A2 (en) | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20030068636A1 (en) | 2001-06-21 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| DK1572087T3 (en) | 2002-03-08 | 2008-08-25 | Pdl Biopharma Inc | Antibodies with cancer antigen TMEFF2 and applications thereof |
| DK2357006T3 (en) | 2002-07-31 | 2015-12-21 | Seattle Genetics Inc | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| RS20050577A (en) | 2003-01-27 | 2007-09-21 | Biogen Idec Ma Inc., | Compositions and methods for treating cancer using igsf9 and liv-1 |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| KR20050010267A (en) | 2003-07-18 | 2005-01-27 | 삼성전자주식회사 | Etching Apparatus |
| CN1938046B (en) | 2003-11-06 | 2014-03-19 | 西雅图基因公司 | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005058961A2 (en) * | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| KR101068289B1 (en) | 2004-07-30 | 2011-09-28 | 리나트 뉴로사이언스 코퍼레이션 | Antibodies directed against amyloid-beta peptide and methods using same |
| US20060222653A1 (en) * | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| JP2009506790A (en) | 2005-09-07 | 2009-02-19 | メディミューン，エルエルシー | EPH receptor antibody conjugated to toxin |
| WO2007120787A2 (en) | 2006-04-13 | 2007-10-25 | Novartis Vaccines & Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression |
| EP2099823B2 (en) * | 2006-12-01 | 2022-02-09 | Seagen Inc. | Variant target binding agents and uses thereof |
| US20090068195A1 (en) * | 2007-04-23 | 2009-03-12 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| EP2641919A3 (en) * | 2007-11-30 | 2014-05-07 | Glaxo Group Limited | Antigen-binding constructs |
| CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| EP2304631A1 (en) | 2008-06-16 | 2011-04-06 | Sividon Diagnostics GmbH | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
| US20110195995A1 (en) | 2008-10-14 | 2011-08-11 | Wittliff James L | Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| US20110165566A1 (en) | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| KR20120104517A (en) | 2009-09-03 | 2012-09-21 | 제넨테크, 인크. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| PL3156420T3 (en) | 2010-12-06 | 2019-08-30 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| WO2012125712A2 (en) | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| SI2766048T1 (en) | 2012-10-12 | 2015-03-31 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| MA45324A (en) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
| MA50943A (en) | 2017-12-01 | 2020-10-07 | Seattle Genetics Inc | HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF BREAST CANCER |
| KR20210089707A (en) | 2018-11-07 | 2021-07-16 | 크리스퍼 테라퓨틱스 아게 | Anti-LIV1 Immune Cell Cancer Therapy |
| GB201908208D0 (en) | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
-
2011
- 2011-12-06 PL PL16200557T patent/PL3156420T3/en unknown
- 2011-12-06 US US13/990,778 patent/US9228026B2/en not_active Ceased
- 2011-12-06 BR BR122021020513-2A patent/BR122021020513B1/en active IP Right Grant
- 2011-12-06 EP EP16200557.3A patent/EP3156420B1/en active Active
- 2011-12-06 DK DK16200557.3T patent/DK3156420T3/en active
- 2011-12-06 KR KR1020227001675A patent/KR20220011811A/en active Application Filing
- 2011-12-06 ES ES16200557T patent/ES2719548T3/en active Active
- 2011-12-06 LT LTEP11847198.6T patent/LT2648752T/en unknown
- 2011-12-06 SG SG10201510041QA patent/SG10201510041QA/en unknown
- 2011-12-06 MX MX2013006365A patent/MX351027B/en active IP Right Grant
- 2011-12-06 PL PL11847198T patent/PL2648752T3/en unknown
- 2011-12-06 SG SG2013041926A patent/SG190938A1/en unknown
- 2011-12-06 KR KR1020197018015A patent/KR102198189B1/en active IP Right Grant
- 2011-12-06 EP EP18204152.5A patent/EP3461847B1/en active Active
- 2011-12-06 PT PT16200557T patent/PT3156420T/en unknown
- 2011-12-06 HU HUE16200557A patent/HUE043355T2/en unknown
- 2011-12-06 HU HUE18204152A patent/HUE052806T2/en unknown
- 2011-12-06 NZ NZ611468A patent/NZ611468A/en unknown
- 2011-12-06 WO PCT/US2011/063612 patent/WO2012078688A2/en active Application Filing
- 2011-12-06 BR BR112013013781A patent/BR112013013781A2/en not_active Application Discontinuation
- 2011-12-06 PT PT182041525T patent/PT3461847T/en unknown
- 2011-12-06 HU HUE11847198A patent/HUE031726T2/en unknown
- 2011-12-06 ES ES18204152T patent/ES2842895T3/en active Active
- 2011-12-06 CA CA2819038A patent/CA2819038C/en active Active
- 2011-12-06 PL PL18204152T patent/PL3461847T3/en unknown
- 2011-12-06 CN CN201180058876.6A patent/CN103533957B/en active Active
- 2011-12-06 KR KR1020137017660A patent/KR101993921B1/en active IP Right Grant
- 2011-12-06 PT PT118471986T patent/PT2648752T/en unknown
- 2011-12-06 RS RS20170310A patent/RS55843B1/en unknown
- 2011-12-06 DK DK18204152.5T patent/DK3461847T3/en active
- 2011-12-06 CA CA3211246A patent/CA3211246A1/en active Pending
- 2011-12-06 JP JP2013542255A patent/JP6105481B2/en active Active
- 2011-12-06 SI SI201131705T patent/SI3156420T1/en unknown
- 2011-12-06 SI SI201131936T patent/SI3461847T1/en unknown
- 2011-12-06 EP EP11847198.6A patent/EP2648752B1/en active Active
- 2011-12-06 SG SG10201912646UA patent/SG10201912646UA/en unknown
- 2011-12-06 SI SI201131155A patent/SI2648752T1/en unknown
- 2011-12-06 US US15/862,389 patent/USRE48959E1/en active Active
- 2011-12-06 AU AU2011338480A patent/AU2011338480B8/en active Active
- 2011-12-06 DK DK11847198.6T patent/DK2648752T3/en active
- 2011-12-06 ES ES11847198T patent/ES2620264T3/en active Active
- 2011-12-06 KR KR1020207037466A patent/KR20200145867A/en active Application Filing
- 2011-12-06 KR KR1020237013204A patent/KR20230057485A/en not_active Application Discontinuation
- 2011-12-06 RU RU2013130609A patent/RU2608646C2/en active
- 2011-12-06 EP EP20189823.6A patent/EP3786185A1/en active Pending
- 2011-12-06 IL IL299837A patent/IL299837A/en unknown
-
2013
- 2013-05-24 ZA ZA2013/03803A patent/ZA201303803B/en unknown
- 2013-06-05 IL IL226754A patent/IL226754B/en active IP Right Grant
- 2013-06-06 MX MX2020010639A patent/MX2020010639A/en unknown
-
2015
- 2015-11-20 US US14/948,183 patent/US9783608B2/en active Active
-
2017
- 2017-03-02 JP JP2017039373A patent/JP6453924B2/en active Active
- 2017-04-07 HR HRP20170567TT patent/HRP20170567T1/en unknown
- 2017-04-27 CY CY20171100472T patent/CY1118874T1/en unknown
- 2017-06-07 AU AU2017203851A patent/AU2017203851B2/en active Active
- 2017-08-31 US US15/692,424 patent/US20180079810A1/en not_active Abandoned
-
2018
- 2018-09-20 IL IL261900A patent/IL261900A/en unknown
- 2018-12-13 JP JP2018233463A patent/JP6869218B2/en active Active
-
2019
- 2019-04-11 AU AU2019202530A patent/AU2019202530B2/en active Active
- 2019-04-12 CY CY20191100414T patent/CY1121546T1/en unknown
-
2020
- 2020-02-06 US US16/784,069 patent/US20200165335A1/en not_active Abandoned
- 2020-03-25 IL IL273607A patent/IL273607B2/en unknown
- 2020-12-22 CY CY20201101211T patent/CY1123883T1/en unknown
-
2021
- 2021-04-13 JP JP2021067924A patent/JP7166384B2/en active Active
- 2021-06-29 AU AU2021204473A patent/AU2021204473A1/en active Pending
-
2022
- 2022-10-25 JP JP2022170266A patent/JP2023011709A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201303803B (en) | Humanized antibodies to liv-1 and use of same to treat cancer | |
| HUS1900007I1 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| IL237960B (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
| EP2604626A4 (en) | Fragment of humanized anti-egfr antibody substituted-lysine variable fragment and use thereof | |
| HK1201855A1 (en) | Antibodies and methods of treating cancer | |
| EP2700652A4 (en) | Diagnosis and treatment of cancer using anti-itm2a antibody | |
| PT2550296T (en) | Monoclonal antibodies for treatment of cancer | |
| EP2575882A4 (en) | Humanized monoclonal antibodies and methods of use |